Saudi Arabia Mrna Therapeutics Market Size & Outlook
Saudi Arabia mrna therapeutics market, 2021-2030 (US$M)
Related Markets
Saudi Arabia mrna therapeutics market highlights
- The Saudi Arabia mrna therapeutics market generated a revenue of USD 136.1 million in 2023 and is expected to reach USD 287.9 million by 2030.
- The Saudi Arabia market is expected to grow at a CAGR of 11.3% from 2024 to 2030.
- In terms of segment, infectious diseases was the largest revenue generating application in 2023.
- Infectious Diseases is the most lucrative application segment registering the fastest growth during the forecast period.
Mrna therapeutics market data book summary
| Market revenue in 2023 | USD 136.1 million |
| Market revenue in 2030 | USD 287.9 million |
| Growth rate | 11.3% (CAGR from 2023 to 2030) |
| Largest segment | Infectious diseases |
| Fastest growing segment | Infectious Diseases |
| Historical data | 2021 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Infectious Diseases |
| Key market players worldwide | Moderna Inc, BioNTech SE ADR, CureVac NV Ordinary Shares, Arcturus Therapeutics Holdings Inc, Sanofi SA, GSK PLC, Pfizer Inc, AstraZeneca PLC, Argos Therapeutics, ETHRIS |
Other key industry trends
- In terms of revenue, Saudi Arabia accounted for 1.2% of the global mrna therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia mrna therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 140.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
MRNA Therapeutics Market Scope
MRNA Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Saudi Arabia mrna therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna therapeutics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Saudi Arabia mrna therapeutics market based on infectious diseases covering the revenue growth of each sub-segment from 2021 to 2030.
The biologics industry in Saudi Arabia is growing rapidly, with major global players entering the market and partnering with local players & government facilities. For instance, in June 2021, a subsidiary of Astra Industrial Group, Tabuk Pharmaceutical Manufacturing, entered into a partnership with Moderna, Inc.
Furthermore, in August 2023, National Resilience, Inc. (Resilience) and Lifera, a biopharmaceutical company owned by the Public Investment Fund (PIF), announced a nonbinding term sheet for a joint venture in Riyadh, Saudi Arabia.
Lifera will be the controlling owner, with Resilience holding a minority stake, targeting an annual production exceeding 125 million units. The facility plans to export to GCC countries and beyond, exploring additional opportunities in cell and gene therapies and nucleic acids while investing in workforce training & upskilling.
Reasons to subscribe to Saudi Arabia mrna therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Saudi Arabia mrna therapeutics market databook
-
Our clientele includes a mix of mrna therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia mrna therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia mrna therapeutics market from 2021 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Saudi Arabia mrna therapeutics market size, by application, 2021-2030 (US$M)
Saudi Arabia MRNA Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
